Loading

A Perspective from the Trenches: Challenges of Budgeting for Gene Therapies, Innovative Payment Systems That Work for Medicaid Departments and Patients, and What the States Need from CMS

June 03, 2024
Breakout Session
Cell and Gene Therapy and Genome Editing
31AB
Cell and gene-based therapies and their potential to cure disease after a single course of therapy have revolutionized the way biopharmaceutical companies are addressing treatment. While the science behind them is revolutionary, their costs have raised concerns. How will state Medicaid agencies address the budgeting challenges that the new therapies pose? What do manufacturers, states, and patients need from CMS? Join this interactive panel for a look at the prospects and obstacles associated with these therapies, including what payment models will facilitate broader use of cell and gene therapies; how state Medicaid programs are addressing the challenges posed by these innovative yet costly therapies and, what potential actions the U.S. Centers for Medicare & Medicaid Services can take to encourage wider adoption.
Speakers
Thomas Barker
Partner
Foley Hoag LLP
Speakers
Scott McGoohan, JD
Executive Director, Policy and Alliance Development
Vertex Pharmaceuticals
Jay Newman
SVP, Commercial Development, Pricing & Reimbursement
Spark Therapeutics, Inc.
Stuart Portman
Executive Director, Division of Medical Assistance Plans
State of Georgia
James Uli
Senior Vice President and Chief Financial Officer
Rady Children's Hospital and Health Center
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS